Comparative evaluation of probiotics effects on plasma glucose, lipid, and insulin levels in streptozotocin‐induced diabetic rats

Memarrast, Faeghe; Ghafouri‐Fard, Soudeh; Kolivand, Sedighe; Jafary-Nodooshan, Saeedeh; Neyazi, Nadia; Sadroddiny, Esmaeil; Motevaseli, Elahe

doi:10.1002/dmrr.2912

Cited by 25 publications

(10 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some studies have already evaluated the anti-diabetic effects of probiotic strains in animal models 16,[34][35][36][37] , as well as the close association between the gut microbiota and the development of liver injury 19,21,23,[38][39][40] . Gut microbiota modulation may induce beneficial adaptations, including the reduction of oxidative stress and inflammation, attenuation of fibrosis, and decrease of apoptosis and necrosis 38 .…”

Section: Discussionmentioning

confidence: 99%

Saccharomyces boulardii modulates oxidative stress and renin angiotensin system attenuating diabetes-induced liver injury in mice

Barssotti

Abreu

Brandão

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Type 1 diabetes (T1DM) is a chronic disease characterized by hyperglycemia due to a deficiency in endogenous insulin production, resulting from pancreatic beta cell death. Persistent hyperglycemia leads to enhanced oxidative stress and liver injury. Several studies have evaluated the anti-diabetic and protective effects of probiotic strains in animal models. In the present study, we investigated, through histopathological and biochemical analyses, the effects of eight weeks of administration of Saccharomyces boulardii (S. boulardii) yeast on the liver of streptozotocin (STZ) induced diabetic C57BL/6 mice. Our results demonstrated that S. boulardii attenuates hepatocytes hydropic degeneration and hepatic vessels congestion in STZ-induced diabetic mice. The treatment attenuated the oxidative stress in diabetic mice leading to a reduction of carbonylated protein concentration and increased activity of antioxidant enzymes superoxide dismutase and glutathione peroxidase, compared to untreated diabetic animals. The results also show the beneficial influence of S. boulardii in regulating the hepatic concentration of renin angiotensin system (RAS) peptides. Therefore, our results demonstrated that S. boulardii administration to STZ-induced diabetic mice reduces oxidative stress and normalizes the concentration of RAS peptides, supporting the hypothesis that this yeast may have a role as a potential adjunctive therapy to attenuate diabetes-induced liver injury.

show abstract

Section: Discussionmentioning

confidence: 99%

Saccharomyces boulardii modulates oxidative stress and renin angiotensin system attenuating diabetes-induced liver injury in mice

Barssotti

Abreu

Brandão

et al. 2021

Sci Rep

View full text Add to dashboard Cite

show abstract

“…However, the efficacy of VSL#3 on diabetes has been researched in obesity and non-obesity murine models [ 73 ]. Curiously, in two CTs [ 47 , 48 ], supplementation with different single strains of L. reuteri increased BMI but maintained the levels of lipid profiles and glucose, improving insulin sensitivity and insulin secretion in healthy and obese populations [ 74 , 75 ]. L. paracasei ssp.…”

Section: Discussionmentioning

confidence: 99%

Probiotic Strains and Intervention Total Doses for Modulating Obesity-Related Microbiota Dysbiosis: A Systematic Review and Meta-analysis

et al. 2020

View full text Add to dashboard Cite

Obesity is a growing health threat worldwide. Administration of probiotics in obesity has also parallelly increased but without any protocolization. We conducted a systematic review exploring the administration pattern of probiotic strains and effective doses for obesity-related disorders according to their capacity of positively modulating key biomarkers and microbiota dysbiosis. Manuscripts targeting probiotic strains and doses administered for obesity-related disorders in clinical studies were sought. MEDLINE, Scopus, Web of Science, and Cochrane Library databases were searched using keywords during the last fifteen years up to April 2020. Two independent reviewers screened titles, abstracts, and then full-text papers against inclusion criteria according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. From 549 interventional reports identified, we filtered 171 eligible studies, from which 24 full-text assays were used for calculating intervention total doses (ITD) of specific species and strains administered. Nine of these reports were excluded in the second-step because no specific data on gut microbiota modulation was found. Six clinical trials (CT) and 9 animal clinical studies were retained for analysis of complete outcome prioritized (body mass index (BMI), adiposity parameters, glucose, and plasma lipid biomarkers, and gut hormones). Lactobacillus spp. administered were double compared to Bifidobacterium spp.; Lactobacillus as single or multispecies formulations whereas most Bifidobacteria only through multispecies supplementations. Differential factors were estimated from obese populations’ vs. obesity-induced animals: ITD ratio of 2 × 106 CFU and patterns of administrations of 11.3 weeks to 5.5 weeks, respectively. Estimation of overall probiotics impact from selected CT was performed through a random-effects model to pool effect sizes. Comparisons showed a positive association between the probiotics group vs. placebo on the reduction of BMI, total cholesterol, leptin, and adiponectin. Moreover, negative estimation appeared for glucose (FPG) and CRP. While clinical trials including data for positive modulatory microbiota capacities suggested that high doses of common single and multispecies of Lactobacillus and Bifidobacterium ameliorated key obesity-related parameters, the major limitation was the high variability between studies and lack of standardized protocols. Efforts in solving this problem and searching for next-generation probiotics for obesity-related diseases would highly improve the rational use of probiotics.

show abstract

“…PB also had a significant effect on adipose Pparγ expression (Hedges' g was 2•0, where a Hedges' g of 0•8 is considered a large effect size (36,57) ). PB supplementation (Lactobacillus reuteri, Lactobacillus crispatus, Bacillus subtilis (58) and Lactobacillus casei, B. bacterium longum (59) ) has previously been associated with enhanced PPARγ activation in HFD-and STZ-induced rodent models of obesity and diabetes (58,59) . Several studies similarly suggest that the PB compound VSL#3 exerts its beneficial effects through PPARγ-dependent mechanisms (60)(61)(62) .…”

Section: Effects Of Probioticsmentioning

confidence: 99%

The effects of myo-inositol and probiotic supplementation in a high-fat-fed preclinical model of glucose intolerance in pregnancy

et al. 2019

View full text Add to dashboard Cite

Glucose intolerance during pregnancy – a major driver of gestational diabetes mellitus (GDM) – has significant short- and long-term health consequences for both the mother and child. As GDM prevalence continues to escalate, there is growing need for preventative strategies. There is limited but suggestive evidence that myo-inositol (MI) and probiotics (PB) could improve glucose tolerance during pregnancy. The present study tested the hypothesis that MI and/or PB supplementation would reduce the risk of glucose intolerance during pregnancy. Female C57BL/6 mice were randomised to receive either no treatment, MI, PB (Lactobacillus rhamnosus and Bifidobacterium lactis) or both (MIPB) for 5 weeks. They were then provided with a high-fat diet for 1 week before mating commenced and throughout mating/gestation, while remaining on their respective treatments. An oral glucose tolerance test occurred at gestational day (GD) 16·5 and tissue collection at GD 18·5. Neither MI nor PB, separately or combined, improved glucose tolerance. However, MI and PB both independently increased adipose tissue expression of Ir, Irs1, Akt2 and Pck1, and PB also increased Pparγ. MI was associated with reduced gestational weight gain, whilst PB was associated with increased maternal fasting glucose, total cholesterol and pancreas weight. These results suggest that MI and PB may improve insulin intracellular signalling in adipose tissue but this did not translate to meaningful differences in glucose tolerance. The absence of fasting hyperglycaemia or insulin resistance suggests this is a very mild model of GDM, which may have affected our ability to assess the impact of these nutrients.

show abstract

Comparative evaluation of probiotics effects on plasma glucose, lipid, and insulin levels in streptozotocin‐induced diabetic rats

Abstract: The results of this experiment showed that daily consumption of probiotics can be effective in control of STZ-induced diabetes and its complications.

Cited by 25 publications

References 19 publications

Saccharomyces boulardii modulates oxidative stress and renin angiotensin system attenuating diabetes-induced liver injury in mice

Saccharomyces boulardii modulates oxidative stress and renin angiotensin system attenuating diabetes-induced liver injury in mice

Probiotic Strains and Intervention Total Doses for Modulating Obesity-Related Microbiota Dysbiosis: A Systematic Review and Meta-analysis

The effects of myo-inositol and probiotic supplementation in a high-fat-fed preclinical model of glucose intolerance in pregnancy

Contact Info

Product

Resources

About